7-OH Product Formats: What Actually Differs Between Tablets, Powders, and Extracts

The five formats, side by side

Labeling precision: per-unit vs. per-container

The single biggest structural difference between formats is what the number on the label refers to. Tablets, chewables, and gummies are per-unit formats: the label states milligrams of 7-hydroxymitragynine per piece, and every piece is supposed to match it. Retail tablets in 2026 commonly run in the 15–30 mg range per tablet and ship in 10-, 20-, and 50-count bottles, so a buyer can multiply count by strength and know the total alkaloid the bottle claims to contain before opening it.

Powder works differently. It is sold by mass of material — typically 1 g or 5 g jars — with a purity percentage on the certificate rather than a per-serving figure. A jar labeled "1 g, 98% purity" contains roughly 980 mg of alkaloid in total, but dividing that into consistent portions is entirely on the buyer and their scale. Liquid extracts split the difference, stating mg per bottle or per mL, which is only as trustworthy as the mixing that keeps the alkaloid evenly suspended in the liquid.

For a concrete example of per-unit labeling done the transparent way, the Favor'd Alkz tablet collection lists a stated milligram strength on every product and ties each batch to a published lab result — the label, the count, and the COA all describe the same unit.

COA batch-matching: which formats you can actually verify

A Certificate of Analysis is only useful if you can compare it to the thing in your hand. Per-unit formats make that comparison one step: the lab reports mg of 7-OH per tablet, the label claims mg per tablet, and the two either agree or they don't. That is why tablets have become the reference format for transparency-focused vendors — verification requires no math beyond reading two numbers.

Powder verification is a percentage exercise. The COA states purity (say, 97.4%), and the buyer must trust that the jar was filled from the tested lot and weigh portions themselves. Liquids add a homogeneity question: a bottle-level mg claim assumes the alkaloid is evenly distributed, which a single lab draw can't fully prove. Gummies are per-unit on the label but carry the most production variance — the alkaloid is stirred into a heated gelatin or pectin base, and uneven mixing shows up as piece-to-piece spread that only a multi-unit lab test catches. 7ohBlack's gummies-versus-tablets comparison walks through why pressed tablets tend to hold tighter unit consistency than gummy formats.

Whatever the format, the checklist is the same: the COA should be batch-specific (lot number matching your container), recent, and issued by an ISO/IEC 17025-accredited laboratory. A generic "sample COA" with no lot number verifies nothing.

Shelf stability and portability

Pressed tablets are the most stable format for straightforward physical reasons: the material is dry, compressed to minimal surface area, and usually sealed with a desiccant. Fine powder is the opposite case — maximum surface area exposed to air and humidity every time the jar opens, and it clumps in humid climates. Liquids have the shortest practical life once opened and are the most sensitive to light and heat in transit. Gummies sit in the middle; a gelatin matrix protects the contents but softens and can melt in a hot mailbox or car, which is a real consideration for summer shipping.

Portability follows the same ranking. A sealed tablet bottle survives a bag or glovebox; loose powder requires a scale to be meaningful anywhere; a glass shot bottle is the bulkiest way to carry the smallest amount of material.

Cost per milligram: the math vendors don't put on the label

Comparing formats on sticker price is meaningless — the honest unit is dollars per milligram of stated 7-OH. The arithmetic is simple: divide the price by (count × mg per unit). A 20-count bottle of 15 mg tablets at $60 works out to $0.20 per mg; a 50-count of the same strength at $115 drops to about $0.15 per mg. Bulk powder generally lands well below tablets on this measure because there is no pressing, flavoring, or per-unit packaging in the cost stack — that's the whole reason bulk 7-OH powder exists as a category, and why buyers sourcing at volume for resale tend to shop it that way rather than by the single jar. Liquid shots usually sit at the top of the per-mg range: the packaging, flavoring system, and small per-bottle totals all work against the buyer. Gummies typically price at a premium over tablets at equal milligrams.

What powder saves in per-mg cost it spends in verification burden. The cheaper the milligram, the more of the measurement work has moved from the manufacturer to you.

What dominates the market — and what regulators are watching

By 2026, per-unit formats — tablets and chewables above all — dominate 7-OH retail. Vendors prefer them because a stated mg-per-tablet claim is defensible with a batch COA, and buyers prefer them because that claim is checkable. Regulators, for their part, focus on concentrated formats specifically: the FDA's July 2025 warning letters went to companies marketing 7-OH tablets, gummies, and drink mixes, and the DEA action moving through the process this year — with an earliest possible scheduling date of August 5, 2026 — targets concentrated 7-OH above a defined threshold rather than ordinary whole-leaf kratom. Concentration is the regulatory dividing line, and every format on this page sits on the concentrated side of it. State law is its own patchwork on top of that; verify your current state and local rules before buying anything in this category.

Why this page says nothing about effects or amounts

Plenty of competitor pages pair a format comparison with suggested serving guidance. We don't, and the reason is not caution for its own sake: there is no established human safety data for concentrated 7-OH products, and the FDA has not evaluated them. Any site telling you what amount is appropriate is guessing in an evidence vacuum. The measurable facts — labeling structure, testability, stability, cost — are worth comparing. Anything beyond that isn't information; it's liability dressed as advice.

The short version

Tablets and chewables state a milligram amount per piece and are the easiest format to check against a lab report. Powder is the cheapest per milligram but hands the measuring to you. Liquids cost the most per milligram and age the fastest. Gummies read like tablets on the label but demand the most scrutiny on batch consistency. Pick whichever format you like — but pick it with a lot-matched COA in hand, and know that regulators are treating all of these as concentrated products in 2026.

Frequently asked questions

Are 7-OH tablets better than powder?

Neither is "better" — they trade off differently. Tablets carry a stated mg per piece, making label-to-COA verification a one-step comparison. Bulk powder usually costs less per milligram of alkaloid but shifts measurement onto the buyer, since its COA reports a purity percentage rather than a per-unit amount.

What is the difference between 7-OH gummies and tablets?

Both state mg per piece. Pressed tablets are compressed from a dry blend, which tends to produce tight unit-to-unit consistency. Gummies suspend the alkaloid in a heated gelatin or pectin matrix, where uneven mixing or heat exposure can create more piece-to-piece variance — so batch COAs matter even more for gummies.

What are chewable 7-OH tablets?

Pressed tablets formulated with flavoring and softer excipients so they break down in the mouth instead of being swallowed whole. For labeling and testing purposes they behave like standard tablets: one stated mg amount per piece, verifiable against a batch COA.

Which 7-OH format is easiest to verify against a COA?

Per-unit formats — tablets, chewables, and gummies — because the lab result and the label describe the same unit. Powder COAs report a purity percentage and liquid COAs report concentration per mL or per bottle, both requiring a conversion step before you can compare against what you received.

Which formats are regulators targeting in 2026?

Concentrated ones. The FDA's July 2025 warning letters named 7-OH tablets, gummies, and drink mixes, and the DEA action pending in 2026 — earliest possible scheduling August 5, 2026 — targets concentrated 7-OH above a defined threshold, not ordinary whole-leaf kratom.